On September 20, 2024, Director J Singleton sold 10,300 shares of Viking Therapeutics Inc (VKTX, Financial) at a price of $69.5 per share, as reported in the SEC Filing. Following this transaction, the insider now owns 9,500 shares of the company. The total value of the shares sold by the insider was $715,850.
Viking Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company's lead clinical program, VK5211, is being developed for the treatment of patients recovering from non-elective hip fracture surgery.
Over the past year, J Singleton has sold a total of 52,786 shares of Viking Therapeutics Inc and has not made any purchases of the stock. This recent transaction is part of a broader trend observed within the company, where there have been 19 insider sells and no insider buys over the past year.
On the day of the transaction, Viking Therapeutics Inc shares were trading at $69.5, giving the company a market cap of approximately $7.82 billion. This valuation reflects the company's position in the market and investor expectations for its future growth prospects.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This insider sell event provides investors with insight into the actions of key executives and may influence market perceptions of Viking Therapeutics Inc's stock.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
